Publication | Closed Access
Hormonal and Metabolic Profiles in Subjects with Obstructive Sleep Apnea Syndrome and the Acute Effects of Nasal Continuous Positive Airway Pressure (CPAP) Treatment
155
Citations
0
References
1995
Year
AsthmaMetabolic DisorderAcute EffectsSleep-related Breathing DisorderObesityMetabolic SyndromeBody CompositionObstructive Sleep ApneaHealth SciencesSleepGrowth HormoneInsulin ManagementEndocrinologySleep Disordered BreathingNocturnal SecretionSleep DisorderMetabolic ProfilesPhysiologyDiabetesSleep ApneaMetabolismMedicineAnesthesiology
Nocturnal secretion of growth hormone is impaired in patients with obstructive sleep apnea (OSA), but the metabolic consequences have not been reported. We measured blood levels of the hormones insulin, C-peptide, growth hormone, cortisol and glucagon together with the intermediary metabolites of carbohydrate (glucose, pyruvate, lactate, alanine) and lipid metabolism [glycerol, nonesterified fatty acids (NEFA), 3-hydroxybutyrate] in six obese nondiabetic men with OSA on two nights. In the first study, the untreated subjects showed frequent apneas and consequent hypoxemia. The hormone and metabolite concentrations were compared with those obtained on the following night when the subjects were treated effectively with nasal continuous positive airway pressure (CPAP). There were no significant differences in the concentrations of insulin, C-peptide, cortisol or glucagon. We confirmed a marked reduction in growth hormone concentrations in OSA, with a significant increase on the CPAP night. The nocturnal profiles of glucose, pyruvate, lactate, alanine and glycerol showed no differences between the two nights, but concentrations of NEFA and 3-hydroxybutyrate, both products of lipolysis, were significantly greater on the treatment night. Because growth hormone has a lipolytic action, the results suggest that suppression of secretion of growth hormone in untreated OSA results in impaired lipolysis, which is rapidly reversed by nasal CPAP.